Back
Capricor investors face Sept. 28, 2026 lead-plaintiff deadline in securities class action

Capricor investors face Sept. 28, 2026 lead-plaintiff deadline in securities class action

The proposed suit covers buyers from Dec. 17, 2025 to July 26, 2026 and centers on allegations that Capricor misled investors about HOPE-3 trial results and FDA-related changes to its statistical analysis plan.

Fact Check
The Hagens Berman HBSS release confirms the firm's investigation of Erasca over ERAS-0015 with the exact class period (Jan 14, 2025–Apr 26, 2026) and Aug 10, 2026 deadline, and allegations spanning preclinical comparisons, IP/patent disputes, and safety risks. The Schall, Brown & Schwartz (SBS) release independently corroborates the same class period, deadline, and ERAS-0015 preclinical/IP focus. The DJS Law Group and Levi & Korsinsky releases further corroborate the class period, deadline, and ERAS-0015 allegations. Every element of the claim is supported by multiple independent sources with no conflicting evidence.
Summary

Capricor Therapeutics, Inc. investors who purchased securities between Dec. 17, 2025 and July 26, 2026 have until Sept. 28, 2026 to seek appointment as lead plaintiff in a proposed securities class action highlighted by Hagens Berman. The suit alleges Capricor and certain executives made materially false and misleading statements about clinical trial data and the regulatory pathway for Deramiocel, its lead product candidate for Duchenne muscular dystrophy. The complaint focuses on allegations that Capricor changed its pre-specified statistical analysis plan without agreement from the U.S. Food and Drug Administration before resubmitting its Biologics License Application. The dispute followed Capricor's Dec. 3, 2025 announcement of positive topline Phase 3 HOPE-3 results, which the company said showed statistically significant improvements in skeletal and cardiac function and helped send the stock up $23.60, or 370%, that day. After the company launched a public offering the next day of about 6 million shares priced at $25 each, the FDA on July 27, 2026 published a briefing document stating HOPE-3 did not meet its pre-specified primary and secondary efficacy endpoints and describing multiple SAP changes. Capricor shares then fell about 64% to close at $7 on July 27. Investors do not need to serve as lead plaintiff to share in any potential recovery.

Terms & Concepts
  • lead plaintiff: The investor appointed by the court to represent the proposed class and help oversee the litigation.
  • statistical analysis plan: A pre-specified framework for analyzing clinical trial data to assess whether a study met its efficacy and safety endpoints.
  • Biologics License Application: A submission to the U.S. Food and Drug Administration seeking approval to market a biologic treatment.